Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus

Next Previous
Trial Profile

Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Anakinra (Primary) ; Etanercept (Primary) ; Liraglutide (Primary) ; Plerixafor (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Jul 2018 Planned primary completion date changed from 30 Jun 2022 to 30 Aug 2022.
    • 21 Nov 2017 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top